Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Application based on results from the TROPION-Lung01 phase 3 trial



If approved, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan may be the first TROP2 directed antibody drug conjugate...

Related Keywords

Japan ,United States ,Sapporo ,Hokkaido ,American ,America ,Ken Takeshita ,Susan Galbraith ,Ann Onc ,Daiichi Sankyo ,Drug Administration ,European Society For Medical Oncology ,Anticancer Research ,American Cancer Society ,Astrazeneca ,National Cancer Institute ,Merck Co Inc ,Nasdaq ,Sapporo Medical University ,Biologics License Application ,Prescription Drug User Fee Act ,Presidential Symposium ,European Society ,Medical Oncology ,Global Head ,Executive Vice President ,North America ,Datopotamab Deruxtecan ,Astrazeneca Collaboration ,Non Small Cell ,Accessed February ,Statistics Factsheets ,Bronchus Cancer ,Targeted Drug Therapy ,Non Small Cell Lung ,Markets ,